Hong Kong, December 21, 2021 — WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the company has been awarded “Excellence in Corporate Governance” of the 2021 Hong Kong Corporate Governance and ESG Excellence Awards. The award recognizes WuXi Biologics’ “success in protecting clients’ interests and well-being of patients”, as well as “the able leadership of its effective and professional board”. WuXi Biologics is the only biotech company among the winners.
The Hong Kong Corporate Governance and ESG Excellence Awards are conferred annually by the Chamber of Hong Kong Listed Companies (CHKLC) and the Centre for Corporate Governance and Financial Policy, Hong Kong Baptist University (CCGFP) and are designed to encourage improvement in corporate governance (CG) and ESG of listed companies in Hong Kong. Winners are considered achieving outstanding commitment to shareholder rights, compliance, integrity, fairness, responsibility, accountability, transparency, board independence and leadership, and ESG.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “To WuXi Biologics, corporate compliance in IP, data protection, codes of business conducts are part of our DNA and reflect how we operate the company sustainably, serve our customers, and comply with external regulations. We are committed to the industry leading governance in our business to enable our clients and to serve patients worldwide.”
WuXi Biologics regards ESG as the core of its sustainability strategies. WuXi Biologics formed its ESG committee in early 2021, responsible for formulating the Company’s sustainable development strategies, guiding and overseeing the implementation across the company. It comprises executive and non-executive directors, as well as independent non-executive directors, leading an ESG task force team covering multiple departments. Under supervision of the board and direct guidance of CEO, WuXi Biologics made continuous progress and was awarded the “CSR Enterprise” by Southern Weekend, as well as the “Best ESG Company” by Institutional Investor in 2021. Meanwhile, WuXi Biologics aims to reduce Greenhouse Gas (GHG) emission intensity by 50% by 2030 from a 2020 baseline.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients.
The company is currently conducting on behalf of its clients and partners (as of June 30, 2021) a total of 408 integrated projects, including 212 in pre-clinical development stage, 160 in early-phase (phase I and II) clinical development, 32 in late-phase (phase III) development and 4 in commercial manufacturing. With a total estimated capacity of exceeding 430,000 liters for biopharmaceutical production planned after 2024 in China, Ireland, the U.S., Germany, and Singapore, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and aims to become a global ESG leader in biologics manufacturing. We use next-generation clean biomanufacturing technologies and utilize cleaner energy sources. We have also established an ESG committee led by the CEO to increase efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.